ORG Partners’s Creative Medical Technology CELZ Stock Holding History

ORG Partners’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80	Closed	-$160	–	1538
2025 Q1	$160	Buy	+80	New	+$279	﹤0.01%	1351

Other funds holding CELZ

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

AAS

Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ORG Partners's CELZ Position: Q2 2025 in Review

ORG Partners sold out of Creative Medical Technology (CELZ) in Q2 2025, closing a stake of 80 shares — an estimated $160 sold.

ORG Partners first reported a position in CELZ in Q1 2025 and held it in 1 quarter. The position peaked at $160 in Q1 2025. 12 funds tracked by Wall St. Rank hold CELZ as of Q2 2025.

ORG Partners reported no remaining Creative Medical Technology position as of Q2 2025 after selling out during the quarter.
ORG Partners sold 80 Creative Medical Technology shares in Q2 2025, an estimated $160.
ORG Partners first reported a position in Creative Medical Technology in Q1 2025 and held it in 1 quarter.
ORG Partners's Creative Medical Technology position peaked at $160 in Q1 2025.
12 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2025.

Based on ORG Partners's 13F filing for Q2 2025, filed 16 Jul 2025.